Suplatast Tosilate
94055-76-2CCOCC(O)COc1ccc(NC(=O)CC[S+](C)C)cc1.Cc1ccc(S(=O)(=O)[O-])cc1RYVJQEZJUFRANT-UHFFFAOYSA-Nstructure given in first source; inhibits antigen-produced histamine release from mast cells; inhibits IgE antibody formation
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.
Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only.
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
用途インターロイキン産生抑制作 用を示します。IgE 産生、好酸球浸潤、ヒス タミンの放出を抑制し、免疫を調節します。
説明Suplatast tosylate is a unique dimethylsulfonium salt marketed in Japan for the treatment of bronchial asthma, atopic dermatitis and allergic rhinitis. Suplatast tosylate is a potent inhibitor of IgE synthesis without suppressing IgM and IgG. The mechanism of action for suplatast tosylate is thought to be via the inhibition of interleukin-4 and interleukin-6 production by T-cells at the gene level. In allergic patients, suplatast tosylate markedly improved clinical symptoms which correlated with a significant decrease in serum IgE antibody levels.
使用Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.
94055-76-2DTXSID9045003CHEMBL115435